Adaptimmune Therapeutics (ADAP)

Adaptimmune Limited • Adaptimmune LLC • Adaptimmune B.V. • CM Intermediate Sub I, Inc. • CM Intermediate Sub II, Inc. • TCR² Therapeutics Inc. • TRUCS Therapeutics Limited • TRUC Securities Corporation ...

ADAP stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

8-K

Adaptimmune Announces Changes to its Executive Leadership Team Based in the UK

13 Nov 24

Adaptimmune Reports Q3 2024 Financial and Business Updates

13 Nov 24

8-K

Adaptimmune’s Lete-cel Achieves Primary Endpoint in Pivotal Trial

13 Nov 24

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

1 Nov 24

8-K

Entry into a Material Definitive Agreement

12 Aug 24

Adaptimmune Reports Q2 2024 Financial and Business Updates

12 Aug 24

8-K

Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy

2 Aug 24

8-K

Departure of Directors or Certain Officers

16 Jul 24

Transcripts

View all

ADAP

Earnings call transcript

2024 Q3

13 Nov 24

ADAP

Earnings call transcript

2024 Q2

12 Aug 24

ADAP

Earnings call transcript

2024 Q1

15 May 24

ADAP

Earnings call transcript

2023 Q4

6 Mar 24

ADAP

Earnings call transcript

2023 Q3

8 Nov 23

ADAP

Earnings call transcript

2023 Q2

9 Aug 23

ADAP

Earnings call transcript

2023 Q2

9 Aug 23

ADAP

Earnings call transcript

2023 Q1

12 May 23

ADAP

Earnings call transcript

2022 Q4

6 Mar 23

ADAP

Earnings call transcript

2022 Q3

8 Nov 22

Latest ownership filings

View all

William C Bertrand JR

20 Feb 25

Joanna Elizabeth Brewer

Long Focus Capital Management, LLC

11 Feb 25

Elliot Norry

17 Jan 25

Financial summary

Financial statements Chart ADAP financial data

Quarter (USD)	Sep 24	Jun 24	Dec 23	Sep 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	119.42 mm	119.42 mm	119.42 mm	119.42 mm	119.42 mm	119.42 mm
Cash burn (monthly)	31.75 mm	(no burn)	5.60 mm	3.60 mm	18.15 mm	9.52 mm
Cash used (since last report)	161.33 mm	n/a	28.43 mm	18.30 mm	92.23 mm	48.39 mm
Cash remaining	-41.91 mm	n/a	90.99 mm	101.12 mm	27.20 mm	71.03 mm
Runway (months of cash)	-1.3	n/a	16.3	28.1	1.5	7.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ADAP institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	79	82	-3.7%
Opened positions	12	17	-29.4%
Closed positions	15	12	+25.0%
Increased positions	18	21	-14.3%
Reduced positions	21	15	+40.0%

13F shares	Current	Prev Q	Change
Total value	66.75 bn	143.98 bn	-53.6%
Total shares	226.87 mm	254.17 mm	-10.7%
Total puts	16.30 k	5.80 k	+181.0%
Total calls	34.20 k	60.80 k	-43.8%
Total put/call ratio	0.5	0.1	+399.6%

Largest owners	Shares	Value	Change
New Enterprise Associates 14	102.48 mm	$150.64 mm	0.0%
EcoR1 Capital	27.40 mm	$14.76 bn	0.0%
Long Focus Capital Management	20.49 mm	$11.04 bn	+54.1%
NEA Management	17.08 mm	$9.20 bn	0.0%
Kairos Capital Management	14.84 mm	$7.99 bn	NEW
Baillie Gifford & Co	11.82 mm	$6.37 bn	-29.5%
MPM Asset Management	5.56 mm	$2.99 bn	0.0%
MPM Oncology Impact Management	5.10 mm	$2.75 bn	0.0%
Partner Fund Management	4.87 mm	$2.62 bn	-51.3%
BAC Bank of America	2.86 mm	$1.54 bn	-38.5%

Largest transactions	Shares	Bought/sold	Change
Matrix Capital Management	0.00	-37.68 mm	EXIT
Kairos Capital Management	14.84 mm	+14.84 mm	NEW
Long Focus Capital Management	20.49 mm	+7.19 mm	+54.1%
Partner Fund Management	4.87 mm	-5.13 mm	-51.3%
Baillie Gifford & Co	11.82 mm	-4.96 mm	-29.5%
BAC Bank of America	2.86 mm	-1.79 mm	-38.5%
Renaissance Technologies	2.53 mm	+869.95 k	+52.5%
Millennium Management	29.56 k	-685.79 k	-95.9%
Acadian Asset Management	510.22 k	+510.22 k	NEW
MS Morgan Stanley	1.32 mm	-374.16 k	-22.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ADAP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Feb 25	Adrian Rawcliffe	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.0013	3,428,832	4.46 k	3,428,832
20 Feb 25	Adrian Rawcliffe	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.1	5,143,248	514.32 k	5,143,248
20 Feb 25	Cintia Piccina	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.0013	1,074,696	1.40 k	1,074,696
20 Feb 25	Cintia Piccina	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.1	1,612,032	161.20 k	1,612,032
20 Feb 25	Elliot Norry	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.0013	1,074,696	1.40 k	1,074,696
20 Feb 25	Elliot Norry	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.1	1,612,032	161.20 k	1,612,032
20 Feb 25	John Lunger	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.0013	1,074,696	1.40 k	1,074,696
20 Feb 25	John Lunger	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.1	1,612,032	161.20 k	1,612,032
20 Feb 25	Bertrand William C JR	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.0013	1,074,696	1.40 k	1,074,696
20 Feb 25	Bertrand William C JR	Option to purchase Ordinary Shares Ordinary Shares	Grant	Acquire A	No	No	0.1	1,612,032	161.20 k	1,612,032

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Adaptimmune Reports Breakthrough Therapy Designation From FDA For Letetresgene Autoleucel In Treating MRCLS After Anthracycline Chemotherapy With 43% Response Rate; Synovial Sarcoma Shows 41% Response In Phase II Trial; Updates To Be Provided At J.P. Morgan Healthcare Conference

13 Jan 25

The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assetsAdaptimmune Allo-T program to be featured at the Biotech

Press releases

From Benzinga Pro

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

30 Jan 25

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ:ADAP), a company working to redefine the treatment of solid tumor cancers with cell

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

13 Jan 25

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

19 Dec 24

Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025Gavin Wood, Chief Financial Officer, will step down from the Company May